Výsledky vyhledávání - "Ángela D Tuero Iglesias"

Akademický článek

Tratamiento con eritropoyetina recombinante humana, hipertrofia ventricular izquierda y balance beneficio riesgo en la ERC-3b

Autor: Jorge F Pérez-Oliva Díaz, Martha Casanova González, Orosmán Cuesta Panaco, Osniel Bencomo Rodríguez, Beatriz López Tórres, Claudio González, Liván Cruz Benítez, Idrian García García, Ángela D Tuero Iglesias, Carmen M Valenzuela Silva, Pedro A López Saura

Publikováno v: Revista Habanera de Ciencias Médicas, Vol 12, Iss 3, Pp 472-486

Introducción: la anemia renal es frecuente en la enfermedad renal crónica avanzada (ERC 3b-4) y el tratamiento con eritropoyetina recombinante humana la mejora pero aún está a debate cual meta de hemoglobina alcanzar y cuál es su repercusión so

Externí odkaz: https://doaj.org/article/2f239291c38049faaa86f92c92c87b77

Zobrazit plný text záznamu

Heberprot-P's Effect on Gene Expression in Healing Diabetic Foot Ulcers

Autor: Hanlet, Camacho-Rodríguez, Isabel A, Guillen-Pérez, Juan, Roca-Campaña, Julio E, Baldomero-Hernández, Ángela D, Tuero-Iglesias, José A, Galván-Cabrera, Maciel, Rodriguez-Cordero, Daniel O, Palenzuela-Gardón, Jorge, Berlanga-Acosta, Lidia I, Novoa-Pérez

Publikováno v: MEDICC review. 20(3)

NTRODUCTION Diabetic foot ulcers are a chronic complication in patients with diabetes mellitus. They appear as a result of the combination of diabetic polyneuropathy and angiopathy, and in many cases require amputation of the affected extremity. Clin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::48d1576b5c32c7ca02d63a1223134c77
https://pubmed.ncbi.nlm.nih.gov/31242156

Zobrazit plný text záznamu

Clinical evaluation of patients with benign prostatic hyperplasia, treated with the natural product Calprost®: a randomized, controlled study

Autor: Magnelis Machado-Leiva, Daise Jiménez-Rodríguez, Tatiana Festary-Casanovas, Deydree C. Silveira-Pacheco, Emilio S. Barroso-de la Cruz, Mariela Suárez-Reyes, Genma Salas-Cruz, Haydee Wong-Arocha, Roberto Fernández-Viera, Ángela D. Tuero-Iglesias, René Delgado-Hernández, Idrian García-García, Calprost Study Group

Publikováno v: Journal of Pharmacy & Pharmacognosy Research, Vol 4, Iss 5, Pp 187-198 (2016)

Context: Benign Prostatic Hyperplasia (BPH) is a common disease that course with Lower Urinary Tract Symptoms (LUTS), mainly in over 50 years-old men. Commonly indicated drugs such as alpha adrenergic-blockers are life-treatment with some adverse rea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doajarticles::120e233e373b1df847264d8a76179c67
http://jppres.com/jppres/pdf/vol4/jppres16.142_4.5.187.pdf

Zobrazit plný text záznamu

Administration HeberFERON in the eyelid basal cell carcinoma about 2 cases

Autor: Irene Rojas Rondón, Yaquelin Duncan Roberts, Clara Gómez Cabrera, Cuba. Centro de Ingeniería Genética y Biotecnología. La Habana, Ramón Pando Ferrer, Lázara Kenia Ramírez García, Lázaro Vigoa Aranguren, Ángela D. Tuero Iglesias, Cuba. Grupo Empresarial Labiofam. La Habana, Iraldo Bello Rivero, Reinier Hernández Rodríguez

Publikováno v: Bionatura, Vol 1, Iss 2, Pp 71-74 (2016)

Cancer is once again the first cause of death in Cuba, and currently among the Latin-American countries and the third world, thus according to estimates, our country has the highest incidence rate of non-melanoma skin cancer. The Basal cell carcinoma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70c540cfebb80a9760bdb4853aa64adc
https://doi.org/10.21931/rb/2016.01.02.6

Zobrazit plný text záznamu

HeberFERON, formulation based on IFNs alpha2b and gamma for the treatment of non-melanoma skin cancer

Autor: Carmen Valenzuela Silva, Yoddali Ballester Caballero, Yaquelin Duncan Roberts, Lorenzo Anasagasti Angulo, Yanelda Garcia Vega, Jorge Marin Guerra, Katherine Batista, Ángela D. Tuero Iglesias, Edgar Tijerino Arrieta, Yanisel Jiménez Barbán, Leovaldo Alvarez Falcon, Iraldo Bello Rivero, Vladimir Sánchez Linares, Sonia Collazo

Publikováno v: Australasian Medical Journal, Vol 10, Iss 6, Pp 509-515 (2017)

Background Surgery remains the procedure of election for the treatment of non-melanoma skin cancer (NMSC). However, after recurrence, or under surgical complex scenarios, other therapeutic modalities have to be indicated. Immune suppression is associ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf8b3c6e47f4d7b0a9d8abe1aa3fc06d
https://doi.org/10.21767/amj.2017.3013

Zobrazit plný text záznamu

Granulation Response and Partial Wound Closure Predict Healing in Clinical Trials on Advanced Diabetes Foot Ulcers Treated With Recombinant Human Epidermal Growth Factor

Autor: Carmen M Valenzuela-Silva, Elizeth García-Iglesias, José I Fernández-Montequín, Amaurys del Río-Martín, Isis Belkis Yera Alos, Ángela D. Tuero-Iglesias, Odalys González-Díaz, Pedro Lopez-Saura

Publikováno v: Diabetes Care

OBJECTIVE To determine if partial wound closure surrogate markers proposed for neuropathic, small diabetic foot ulcers (DFUs) can be extended to advanced lesions and if the development of granulation tissue can be used to predict complete healing. RE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::601c6391d0c5aa14e57248849eb1cda0
https://doi.org/10.2337/dc12-1323

Zobrazit plný text záznamu

Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

Autor: Liuba Alonso-Carbonell, Ivonne Marrero-Rodríguez, Martha Moreira-Martínez, Carmen M Valenzuela-Silva, Ángela D. Tuero-Iglesias, Pedro A López-Saura, Isis B Yera-Alos, Ernesto López-Mola

Publikováno v: BMC Pharmacology & Toxicology

Background After several exploratory and confirmatory clinical trials, the intralesional administration of human recombinant epidermal growth factor (hrEGF) has been approved for the treatment of advanced diabetic foot ulcers (DFU). The aim of this w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58238a6c3d03d8c0cad8bc8f1a7ef26c
https://doi.org/10.1186/2050-6511-14-44

Zobrazit plný text záznamu

Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG®) in patients with mycosis fungoides: an open-label trial

Autor: Iraldo Bello-Rivero, Dania Vazquez-Blomquist, Mileidys Cabrera-Placeres, Yoandy Izquierdo-Toledo, Tania I Carballo-Treto, Idrian García-García, Nailet Castro-Basart, Josanne Soto-Matos, Yaquelin Duncan-Roberts, Sonia E Collazo-Caballero, Elizeth García-Iglesias, Egla E Santely-Pravia, Alieski Cruz-Ramírez, Cristian Alfonso-Alvarado, Ángela D. Tuero-Iglesias, Yanelda García-Vega

Publikováno v: BMC Pharmacology & Toxicology

Background The synergistic combination of interferon (IFN) alpha-2b and IFN gamma results in more potent in vitro biological effects mediated by both IFNs. The aim of this investigation was to evaluate by first time the pharmacokinetics and pharmacod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca8c2c8964f3de88fe55c00ca393ecc
https://doi.org/10.1186/2050-6511-13-20

Zobrazit plný text záznamu

Tratamiento con eritropoyetina recombinante humana, hipertrofia ventricular izquierda y balance beneficio riesgo en la ERC-3b

Publikováno v: Revista Habanera de Ciencias Médicas, Vol 12, Iss 3, Pp 472-486

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doajarticles::ffd46a75877747da9920278360ed6c5a
http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2013000300020&lng=en&tlng=en

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání